Phentermine-topiramate
Phentermine-topiramate has been studied in 15 papers since 2017: 3 observational studies in people, 11 reviews; 6 in the past year. The newest paper, Jun 8, 2026: “Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists”.
15 papers study it1 findingUpdated
See all 15 papers on phentermine-topiramate
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country; 19 trials, none about aging, 2 with no results posted.
- 1 lab in 1 country
- 19 trials, none about aging, 2 with no results posted
- 10 of 19 trials sponsored by its developers
- Humans3
- In silico1
What is phentermine-topiramate linked with?
1Studies link phentermine-topiramate with Cost-effectiveness.
Cost-effectiveness
upin reviews1
1 study
Cost-effectiveness
upin reviews1
Phentermine-topiramate is associated with cost-effectiveness (particularly in low-resource settings).
“Phentermine-topiramate showed acceptable cost-effectiveness, particularly in low-resource settings.”
Reviewparticularly in low-resource settings
Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review
International journal of preventive medicine
Has phentermine-topiramate been tested in people?
0 of 19 about agingYes: 3 observational studies in people have been published, and 12 trials are registered.
In trials
Phase 4Results posted7 trials
Phase 4Results posted2 trials
Phase 4Terminated2 trials
Phase 4Recruiting1 trial
Phase 4Recruiting1 trial
Phase 2Active, not recruiting1 trial
All 11Fewer
Stopped
NCT04531176TerminatedObesity
After an unplanned yet IRB approved interim analysis, it was found that there was not a significant difference between the 3 arms of the study. The study was closed due to futility. All Patients are off study and this study will not resume.
Trial sponsors
Company2 trialsPhase 4172 people
2 trialsPhase 4224 people
2 trialsPhase 4124 people
St. Jude Children's Research Hospital
1 trialPhase 2100 people
University of California, San Diego
1 trialPhase 240 people
Wake Forest University Health Sciences
1 trialPhase 225 people
1 trialPhase 224 people
1 trialPhase 219 people